海角破解版

Compound E

Notch pathway inhibitor; Inhibits Notch receptor and amyloid precursor protein

Compound E

Notch pathway inhibitor; Inhibits Notch receptor and amyloid precursor protein

Catalog #
(Select a product)
Notch pathway inhibitor; Inhibits Notch receptor and amyloid precursor protein
Request Pricing Request Pricing

Overview

Compound E is a potent, cell-permeable, selective inhibitor that blocks the cleavage of both gamma-secretase and the Notch intracellular domain with similar IC50 values, ranging from 0.24 to 0.37 nM (Beher et al.; Seiffert et al.).


DIFFERENTIATION
路 Inhibits growth, differentiation, and motility of neuroblastoma cells (Ferrari-Toninelli et al.).
路 Accelerates the differentiation of human embryonic stem cells into primitive neural stem cells (Li et al.).
Cell Type
Brain Tumor Stem Cells, Neural Cells, PSC-Derived, Neural Stem and Progenitor Cells
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Differentiation, Maintenance
Area of Interest
Neuroscience
CAS Number
209986-17-4
Chemical Formula
颁鈧傗倗贬鈧傗倓贵鈧侼鈧凮鈧"
Purity
鈮 98%
Pathway
Notch
Target
纬-厂别肠谤别迟补蝉别

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
73952, 73954
Lot #
All
Language
English
Document Type
Product Name
Catalog #
73952, 73954
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (5)

Transcriptome-based screening in TARDBP/TDP-43 knock-in motor neurons identifies the NEDD8-activating enzyme inhibitor MLN4924 Scientific Reports 2025 Aug

Abstract

A growing body of knowledge implicates perturbed RNA homeostasis in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that currently has no cure and few available treatments. Dysregulation of the multifunctional RNA-binding protein TDP-43 is increasingly regarded as a convergent feature of this disease, evidenced at the neuropathological level by the detection of TDP-43 pathology in most patient tissues, and at the genetic level by the identification of disease-associated mutations in its coding gene TARDBP. To characterize the transcriptional landscape induced by TARDBP mutations, we performed whole-transcriptome profiling of motor neurons聽(MNs) differentiated from two knock-in iPSC lines expressing the ALS-linked TDP-43 variants p.A382T or p.G348C. Our results show that the TARDBP mutations significantly altered the expression profiles of mRNAs and microRNAs of the 14q32 cluster in MNs. Using mutation-induced gene signatures and the Connectivity Map database, we identified compounds predicted to restore gene expression toward wild-type levels. Among top-scoring compounds selected for further investigation, the NEDD8-activating enzyme inhibitor MLN4924 effectively improved cell viability and neuronal activity, highlighting a possible role for protein post-translational modification via NEDDylation in the pathobiology of TDP-43 in ALS.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-12147-8.
Altered development and network connectivity in a human neuronal model of 15q11.2 deletion-related neurodevelopmental disorders C. Habela et al. Translational Psychiatry 2025 Aug

Abstract

The chromosome 15q11.2 locus is deleted in 1.5% of patients with genetic epilepsy and confers a risk for intellectual disability and schizophrenia. Individuals with this deletion demonstrate increased cortical thickness, decreased cortical surface area and white matter abnormalities. Human induced pluripotent stem cell (iPSC)-derived neural progenitor cells from 15q11.2 deletion individuals exhibit early adhesion junction and migration abnormalities, but later neuronal development and function have not been fully assessed. Imaging studies indicating altered structure and network connectivity in the anterior brain regions and the cingulum suggest that in addition to alterations in neural progenitor dynamics, there may also be structural and functional changes within discrete networks of neurons. To explore this, we generated human forebrain cortical neurons from iPSCs derived from individuals with or without 15q11.2 deletion and used longitudinal imaging and multielectrode array analysis to evaluate neuronal development over time. 15q11.2 deleted neurons exhibited fewer connections and an increase in inhibitory neurons. Individual neurons had decreased neurite complexity and overall decreased neurite length. These structural changes were associated with a reduction in multiunit action potential generation, bursting and synchronization. The 15q11.2 deleted neurons also demonstrated specific functional deficits in glutamate- and GABA-mediated neuronal network activity and synchronization with a delay in the maturation of the inhibitory response to GABA. These data indicate that deletion of the 15q11.2 region is sufficient to impair the structural and functional maturation of cortical neuron networks, and suggest an in vitro correlate to the pathologic changes in humans with the 15q11.2 deletion.
The exocyst subunit EXOC2 regulates the toxicity of expanded GGGGCC repeats in Cell reports 2024 Jun

Abstract

SUMMARY GGGGCC (G4C2) repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). How this genetic mutation leads to neurodegeneration remains largely unknown. Using CRISPR-Cas9 technology, we deleted EXOC2, which encodes an essential exocyst subunit, in induced pluripotent stem cells (iPSCs) derived from C9ORF72-ALS/FTD patients. These cells are viable owing to the presence of truncated EXOC2, suggesting that exocyst function is partially maintained. Several disease-relevant cellular phenotypes in C9ORF72 iPSC-derived motor neurons are rescued due to, surprisingly, the decreased levels of dipeptide repeat (DPR) proteins and expanded G4C2 repeats-containing RNA. The treatment of fully differentiated C9ORF72 neurons with EXOC2 antisense oligonucleotides also decreases expanded G4C2 repeats-containing RNA and partially rescued disease phenotypes. These results indicate that EXOC2 directly or indirectly regulates the level of G4C2 repeats-containing RNA, making it a potential therapeutic target in C9ORF72-ALS/FTD. In brief Halim et al. deleted the gene EXOC2 from patient stem cells and then differentiated them into motor neurons. They found that several amyotrophic lateral sclerosis-related phenotypes were rescued in patient neurons when EXOC2 was deleted or knocked down by a drug. This study identifies EXOC2 as a potential therapeutic target. Graphical Abstract